Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin (TOP)

This study has been terminated.
(Low accrual rate)
Gustave Roussy, Cancer Campus, Grand Paris
Centre Paul Strauss
Centre Hospitalier du Luxembourg
Clinique Louis Cathy - Baudour - Belgium
HIS - Site Etterbeek - Ixelles - Belgium
Clinique Saint Pierre - Ottignies -Belgium
Clinique Ste Elisabeth - Namur - Belgium
University Hospital of Crete
Feculdade de Medicina da Universidade de Sao Paulo - Brasil
Information provided by:
Jules Bordet Institute Identifier:
First received: September 9, 2005
Last updated: July 16, 2008
Last verified: July 2008
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: April 2009
  Estimated Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)